Brenig Therapeutics
- Biotech or pharma, therapeutic R&D
Bayshore Global Management, Bio Generation Ventures, NEA, OrbiMed and Torrey Pines Investment are our investors.
Brenig Therapeutics is focused on creating a LRRK2 inhibitor molecule with improved brain penetration and reduced peripheral toxicity. Torrey Pines Investment and OrbiMed jointly advanced the science and infrastructure and now, with the newly appointed CEO and CMO, Brenig is evolving into a development stage company, aiming for a lean structure with a flexible workforce. The next clinical asset that will expand Brenig’s pipeline is also from this collaboration and focuses on a novel non LRRK2 inhibitor for Parkinson’s disease. Both assets are envisioned to mitigate investment risk by having independent mechanisms of action, as well as potential to have synergistic effect in mitigating autophagy-lysosomal dysfunction and neuroinflammation.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}